Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin

C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: Inhibitory effects of atorvastatin

“…Also, in a similar dose as used in the present study, atorvastatin has been shown to inhibit the expression of resistin [33], lipoprotein and endothelial lipase activity [34]. Though other statins are shown to attenuate CRP-induced expression of certain candidate genes involved in inflammation and atherosclerosis [4,35,36], data with atorvastatin and on RAGE and EN-RAGE is still lacking. Our data highlights important anti-inflammatory properties of atorvastatin which may be mediated by non-steroidal products of the mevalonate pathway.…”

The role of resistin as a regulator of inflammation: Implications for various human pathologies

“…Statins (HMG CoA reductases) have been shown to reduce cardiovascular events and mortality. Statin treatment resulted in a significant reduction of plasma resistin in patients with type 2 diabetes and also downregulated mRNA resistin levels in PBMCs [40,136].…”

“…It has been demonstrated that proinflammatory mediators such as TNF-α, IL-1β, IL-6, or lipopolysaccharide (LPS) can strongly increase the expression of resistin in peripheral blood mononuclear cells (PBMCs), suggesting a role for resistin in the process of inflammation [36][37][38][39]. In addition, C-reactive protein (CRP) induced both mRNA expression and protein secretion of resistin in a dose-and time-dependent manner in PBMCs [40].…”

“…This effect may occur through resistin-mediated phosphorylation of the inhibitory protein IκBα and the p65 subunit of NF-κB [40]. Resistin increased the cytosolic calcium concentration via an influx of calcium from the extracellular environment and activation of phospholipase C (PLC), leading to the release of calcium from intracellular pools [41].…”

Pentoxifylline administration changes protein expression profile of coronary artery disease patients

“…As these processes result in cardiovascular events and even death, inhibition could be a target for prevention and treatment of cardiovascular diseases. Furthermore, studies have shown that drugs atorvastatin (Blanco-Colio et al, 2008;Kinlay et al, 2004;WibautBerlaimont et al, 2005), simvastatin (Hu et al, 2007;Serrano et al, 2009) and ezetimibe (Gomez-Garre et al, 2009) which have an obvious favorable effect on CAD patients also have some immunomodulatory properties that could be an additional mechanism for their effects.…”